(Q36618246)

15 August 2017

Early death during chemotherapy in patients with small-cell lung cancer: derivation of a prognostic index for toxic death and progression (English)

1 reference

15 August 2017

1 reference

1 reference

Lassen UN

1

1 reference

15 August 2017

Osterlind K

2

1 reference

15 August 2017

Hirsch FR

3

1 reference

15 August 2017

Bergman B

4

1 reference

15 August 2017

Dombernowsky P

5

1 reference

15 August 2017

Hansen HH

6

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 February 1999

1 reference

British Journal of Cancer

15 August 2017

1 reference

15 August 2017

79

1 reference

15 August 2017

3-4

1 reference

15 August 2017

515-519

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6690080

15 August 2017

0 references

cites work

Autologous bone marrow transplantation following high-dose chemotherapy with cyclophosphamide, BCNU and VP-16 in small cell carcinoma of the lung and a review of current literature

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362437

Drug monitoring of etoposide (VP16-213). Correlation of pharmacokinetic parameters to clinical and biochemical data from patients receiving etoposide

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362437

Patients at risk of chemotherapy-associated toxicity in small cell lung cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362437

Dose-intensity meta-analysis of chemotherapy regimens in small-cell carcinoma of the lung

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362437

Improvement of long-term survival in extensive small-cell lung cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362437

Management of small cell lung cancer: a summary of the Third International Association for the Study of Lung Cancer Workshop on Small Cell Lung Cancer

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362437

Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362437

Effects of the epipodophyllotoxin VP-16-213 on cell cycle traverse, DNA synthesis, and DNA strand size in cultures of human leukemic lymphoblasts.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362437

A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin, and vincristine for extensive-stage small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group

20 September 2018

1 reference

12 December 2020

Teniposide and etoposide in previously untreated small-cell lung cancer: a randomized study

1 reference

12 December 2020

Randomised trial of four-drug vs less intensive two-drug chemotherapy in the palliative treatment of patients with small-cell lung cancer (SCLC) and poor prognosis. Medical Research Council Lung Cancer Working Party

1 reference

12 December 2020

Superiority of cisplatin or carboplatin in combination with teniposide and vincristine in the induction chemotherapy of small-cell lung cancer. A randomized trial with 5 years follow up

1 reference

12 December 2020

Continuous versus alternating combination chemotherapy for advanced small cell carcinoma of the lung

1 reference

12 December 2020

1 reference

12 December 2020

Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 100 consecutive patients with limited- and extensive-disease small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6690080

7 January 2021

Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial. Medical Research Council Lung Cancer Working Party.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6690080

7 January 2021

The superiority of combination chemotherapy including etoposide based on in vivo cell cycle analysis in the treatment of extensive small-cell lung cancer: a randomized trial of 288 consecutive patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6690080

7 January 2021

Outcome of combination chemotherapy in extensive stage small-cell lung cancer: any treatment related progress?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6690080

7 January 2021

Chemotherapy versus chemotherapy plus irradiation in limited small cell lung cancer. Results of a controlled trial with 5 years follow-up

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6690080

7 January 2021

Combination chemotheraphy of limited-stage small-cell lung cancer. A controlled trial on 221 patients comparing two alternating regimens

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6690080

7 January 2021

Predicting septic complications of chemotherapy: an analysis of 382 patients treated for small cell lung cancer without dose reduction after major sepsis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6690080

7 January 2021

Identifiers

DOI

10.1038/SJ.BJC.6690080

1 reference

Dimensions Publication ID

15 August 2017

0 references

1 reference

15 August 2017

1 reference